REGENXBIO financials
$7.45−0.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.0M | $6.4M | $30.3M | $29.7M | $21.4M | $89.0M | $21.2M | $24.2M | $22.3M | $15.6M | $22.2M | $28.9M |
| Gross profit | $107.0M | -$4.7M | $24.4M | $24.0M | $16.1M | $85.6M | $14.9M | $11.8M | $11.7M | $11.3M | $11.0M | $16.5M |
| Gross margin | 99.0% | −73.2% | 80.5% | 80.7% | 75.6% | 96.1% | 70.2% | 48.8% | 52.5% | 72.6% | 49.4% | 57.2% |
| Operating income | $29.3M | -$83.4M | -$57.6M | -$52.4M | -$63.3M | $12.1M | -$51.4M | -$62.1M | -$56.0M | -$63.9M | -$64.2M | -$64.7M |
| Net income | $22.7M | -$90.1M | -$67.1M | -$61.9M | -$70.9M | $6.1M | -$51.2M | -$59.6M | -$53.0M | -$63.3M | -$62.9M | -$61.9M |
| Net margin | 21.0% | −1408.6% | −221.3% | −208.3% | −331.8% | 6.8% | −241.3% | −246.3% | −237.7% | −405.4% | −283.1% | −214.0% |
| Diluted EPS | $0.43 | $-1.72 | $-1.30 | $-1.20 | $-1.38 | $0.12 | $-1.01 | $-1.17 | $-1.05 | $-1.38 | $-1.43 | $-1.41 |
| EBITDA | $33.0M | -$79.5M | -$53.8M | -$48.5M | -$59.4M | $16.1M | -$47.3M | -$58.1M | -$52.0M | -$57.6M | -$59.8M | -$60.4M |
| Operating cash flow | -$62.2M | -$76.2M | -$52.3M | -$56.0M | -$49.3M | $33.6M | -$31.6M | -$40.5M | -$45.5M | -$55.5M | -$40.8M | -$49.4M |
| Free cash flow | -$63.0M | -$77.4M | -$52.8M | -$56.5M | -$49.7M | $32.6M | -$32.7M | -$40.9M | -$46.0M | -$56.0M | -$41.9M | -$50.8M |
| Diluted shares | 53.0M | 52.4M | 51.7M | 51.7M | 51.5M | 51.4M | 50.9M | 50.8M | 50.6M | 45.7M | 44.0M | 43.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $36.5M | $15.2M | $34.5M | $58.8M | $79.6M | $130.1M |
| Short-term investments | $69.0M | $135.3M | $195.6M | $215.4M | $243.7M | $137.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $11.1M |
| Total assets | $386.6M | $341.9M | $453.0M | $525.2M | $581.0M | $490.9M |
| Total liabilities | $314.9M | $320.8M | $350.3M | $363.8M | $367.3M | $216.7M |
| Shareholders' equity | $71.8M | $21.1M | $102.7M | $161.5M | $213.7M | $274.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology